Results 81 to 90 of about 20,263 (262)

Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations

Current Medical Research and Opinion, 2020
Objective: Varenicline, a selective partial agonist of the α4β2 nicotinic acetylcholine receptor, is a smoking cessation pharmacotherapy that more than doubles the chance of quitting smoking at 6 months compared with placebo. This article reviews salient
S. Tonstad, C. Arons, H. Rollema, I. Berlin, P. Hajek, K. Fagerström, C. Els, T. McRae, C. Russ   +8 more
semanticscholar   +1 more source

Looking Back and Going Forward: Roles of Varenicline and Electronic Cigarettes in Smoking Cessation

Cureus, 2021
Tobacco use is the single largest preventable cause of death in the United States (US). The national goal of reducing the prevalence of adult cigarette smoking to 12% was retained for 20 years due to non-attainment.
Ebenezer O. Oloyede, O. Ola, V. Kolade, J. Tevie   +3 more
semanticscholar   +1 more source

Nicotine receptor partial agonists for smoking cessation

São Paulo Medical Journal
BACKGROUND: Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist)
Kate Cahill, Lindsay F. Stead, Tim Lancaster, Igor Bastos Polonio   +3 more
doaj   +1 more source

Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. [PDF]

, 2019
Mood disorders are highly prevalent and are the leading cause of disability worldwide. The neurobiological mechanisms underlying depression remain poorly understood, although theories regarding dysfunction within various neurotransmitter systems have ...
Dulawa, Stephanie C, Janowsky, David S
core  

Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series. [PDF]

, 2015
Psychiatric adverse drug reactions (ADRs) have been reported with statin use, but the literature regarding statin-associated mood/behavioral changes remains limited.
Cham, Stephanie, Golomb, Beatrice A, Koslik, Hayley J   +2 more
core   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Association Between Conflicts of Interest and Authors’ Positions on Harms of Varenicline: a Cross-Sectional Analysis

Journal of general internal medicine, 2021
Few studies have investigated the relationship between industry funding/conflicts of interest and authors’ positions in opinion pieces on drug safety. Harmful effects of varenicline, a treatment for smoking cessation, have been highly contested.
A. Fabbri, C. H. Nejstgaard, Q. Grundy, L. Bero, A. Dunn, Annim Mohammad, B. Mintzes   +6 more
semanticscholar   +1 more source

New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What has been Investigated and What is in the Pipeline? [PDF]

, 2016
A wide range of support is available to help smokers to quit and aid attempts at harm reduction, including three first-line smoking cessation medications: nicotine replacement therapy, varenicline and bupropion.
A Bisaga, A Jackson, A Kukkar, A Lenox-Smith, A Mann, A Parsons, A Sood, A Sood, A Verrotti, AE Evins, AH Glassman, AK Shinn, AM Joseph, AR Buchhalter, AS Rauhut, AV Prochazka, B Gaster, B Pasternak, B Spring, B Westenberger, BA Johnson, BF Grant, BM Kuehn, C Bullen, C Lerman, C Reavill, C Zona, C-Y Yeh, CA Martin, CD Cropp, CE Gartner, CF Koegelenberg, CL Bennett, CL DeVane, CL Strasinger, CT Bolliger, D Gonzales, D Hammond, D Kotz, D Kotz, D Kotz, D Mischoulon, D Moore, DA Baker, DA Baltieri, DA Revicki, Damian M. Cummings, DE Hilleman, DJ Romberger, DK Hatsukami, DK Hatsukami, DK Miller, DP Tashkin, E Beard, E Beard, E Beard, E Gere-Pászti, E Nowakowska, EA Finkelstein, EA Gilpin, EA McClure, EA Zimovetz, EC Westman, ED Levin, EG Guy, EH Cerny, EJ Jensen, EJ Mills, EJ Mills, EJ Wagena, Emma Beard, EW Tuan, F Wang, FT Filippidis, G Addolorato, G Chiara Di, G Cucchiaro, G Sutherland, GA Higgins, GM Keating, H Kitagawa, H McRobbie, H McRobbie, H Minami, H Myrick, H Pine-Abata, H-J Aubin, HM Schuller, I Berlin, J Balmford, J Brown, J Cornuz, J Foulds, J Foulds, J Kaper, J Kay, J Leaviss, J Ollivier, J Rose, J Shearer, J Shearer, J Yang, J-F Etter, J-G Gehricke, JA Dani, JE Henningfield, JE Henningfield, JE Rose, JE Rose, JE Sarginson, JF Rosenbaum, JM Ramon, JM Samet, JN Liberman, JO Ebbert, JO Ebbert, JR DiFranza, JR Hughes, JR Hughes, JS Ballon, JS Brown, JS Fowler, JW Lockner, K Bolin, K Demyttenaere, K Hara, K Ogita, K Silla, KA Holes-Lewis, KA Kasza, KA Perkins, KA Sacco, KC Waterman, KE Dunn, KE Farsalinos, KH Thomas, KP Garnock-Jones, KS Paudel, L Annemans, L Kozlowski, L Leggio, L Lima De, L Schmaal, L Shahab, L Shahab, LF Gaal Van, LH Ferry, Lion Shahab, LS Brose, LS Brose, LS Covey, M Farrell, M Harrison-Woolrych, M Hoogendoorn, M Khalifa, M Lader, M Mahmoudi, M McCarty, M Mugnaini, M Mula, M Neovius, M Ng, M Pravetoni, M Pravetoni, M Raw, M Raw, M Sofuoglu, M Sofuoglu, M Sofuoglu, M Sofuoglu, M Williams, M Wimbiscus, MA Jacobs, MA Russell, MA Russell, MC Fiore, ME Hadwiger, ME Jarvik, ME Jarvik, ME Mooney, ME Page, ME Thase, MFG Murphy, MG LeSage, MG LeSage, MH Ebell, MH Rapaport, ML Goniewicz, MM Moran, MY Bertram, N Benowitz, N Lindblom, N Walker, N Woolacott, NB Edwards, NF Woolacott, NL Benowitz, P Aveyard, P Farid, P Franks, P Gerrard, P Hajek, P Hajek, P Hajek, P Hajek, P Jha, P Maurer, P Popik, PH Hoogsteder, PH Silverstone, PM Bet, PM Cinciripini, PS Masand, R Benyamin, R Freedman, R Niaura, R Niaura, R Ray, R Richmond, R Shytle, R Taylor, R West, R West, R West, R West, R West, R West, R West, RA Brown, RA Schnoll, RA Schnoll, RB Barlow, RC Smith, RD Hurt, RD Hurt, RE Fahim, RF Yoshimura, RM Anthenelli, RM Pinder, Robert West, S Brimijoin, S Denford, S Greenland, S Leonard, S Shiffman, S Shiffman, S Shiffman, S Shiffman, S Singh, S Thornley, S Tonstad, S Tonstad, S Wanwimolruk, SA Ornish, SC Licata, SD Hall, SD Satoskar, SE Adkison, SH Villiers de, SL McElroy, SM Boekholdt, SM Holliday, SP Lakshmi, SS Hecht, Susan Michie, T Blondal, T Green, T Paparrigopoulos, T Raupach, TB Johnstone, TE Langley, TE Meyer, TJ Meine, TL Awtry, TM Luger, TR Franklin, U Eckstein-Ludwig, U Perngparn, V Butterweck, V Gligorijevic, V Klimek, V Varga, V Vengeliene, VS Kumar, W Berrettini, W Hao, W Pichayakorn, W Qiumei, WI Najm, WR Hiatt, X Shen, Y Buggy, Y Khazaal, Y-S Kim   +293 more
core   +1 more source

Gene therapy for epilepsy: An emerging, promising approach for a serious neurological disorder

Journal of Internal Medicine, EarlyView.
Abstract Gene therapy is emerging as a groundbreaking strategy for treating epilepsy, offering new hope to patients who do not respond to conventional medications. Despite advancements in anti‐seizure treatments, nearly 30%–40% of individuals with epilepsy continue to experience uncontrolled seizures, highlighting the urgent need for more effective and
Marco Ledri, Merab Kokaia
wiley   +1 more source

Stability of varenicline concentration in saliva over twenty-one days at three storage temperatures.

Nicotine & Tobacco Research, 2021
INTRODUCTION Varenicline is the most efficacious drug for smoking cessation; saliva varenicline concentrations can be useful for the evaluation of adherence in smoking cessation trials.
M. Novalen, Meghan J. Chenoweth, Bin Zhao, L. Hawk, R. Tyndale   +4 more
semanticscholar   +1 more source